다음 MAP메이트™는 통합될 수 없습니다: -다른 분석 완충용액이 필요한 MAP메이트™. -인산 특이성 및 총 MAP메이트™ 조합, 예: 총 GSK3β 및 GSK3β(Ser 9). -PanTyr 및 자리 특이성 MAP메이트™, 예: Phospho-EGF 수용체 및 phospho-STAT1(Tyr701). -단일 표적(Akt, STAT3)를 위한 1개 이상의 1 phospho-MAP메이트™. - GAPDH 및 β-Tubulin은 panTyr를 포함하는 키트 또는 MAP메이트™와 통합될 수 없습니다.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
이 제품은 즐겨찾기에 저장되었습니다.
종
패널 유형
선택하신 키트
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
96-Well Plate
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
다른 시약 추가 (MAP메이트 사용을 위해 완충용액과 검출 키트가 필요함)
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
공간 절약 옵션 다수의 키트를 구매하시는 고객은 고용량 저장을 위해 키트 포장을 제거하고 비닐백에 담긴 멀티플레스 분석 구성품을 받아 저장 공간을 절약하도록 선택할 수 있습니다.
이 제품은 즐겨찾기에 저장되었습니다.
해당 제품은 고객님의 카트에 추가되었습니다.
이제 다른 키트를 사용자 지정하거나, 사전 혼합된 키트를 선택하거나, 결재하거나 또는 주문 도구를 종료할 수 있습니다.
IM09L
Sigma-AldrichAnti-MMP-9 (Ab-1) Mouse mAb (6-6B)
This Anti-MMP-9 (Ab-1) Mouse mAb (6-6B) is validated for use in Immunoblotting, Immunoprecipitation, Neutralization Studies, Paraffin Sections for the detection of MMP-9 (Ab-1).
More>>This Anti-MMP-9 (Ab-1) Mouse mAb (6-6B) is validated for use in Immunoblotting, Immunoprecipitation, Neutralization Studies, Paraffin Sections for the detection of MMP-9 (Ab-1). Less<<
Anti-MMP-9 (Ab-1) Mouse mAb (6-6B) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Recognizes the ~92 kDa latent and the ~83 kDa active forms of MMP-9 under non-reducing conditions, but only the latent form under reducing conditions. Inhibits the enzymatic activity of MMP-9. For paraffin sections, use Cat. No. IM37L.
Catalogue Number
IM09L
Brand Family
Calbiochem®
Synonyms
Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9, Anti-Type IV Collagenase, Anti-Gelatinase B
References
References
Cottam, D.W. and Rees, R.C. 1993. Intl. J. of Oncol.2, 861. Nakajima, M., et al. 1993. Cancer Res.53, 5802. Ramos-DeSimone, et al. 1993. Hybridoma. 12, 349. Stetler-Stevenson, W.G., et al. 1993. FASEB.7, 1434. Zucker, S., et al. 1993. Cancer Res.53, 140. Woessner, J.F. 1991. FASEB. 5, 2145. Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1; 99-106.
Immunoprecipitation
Ramos-DeSimone, N. and French, D. L. 1994. Ann. NY Acad. Sci.732, 469.
Immunoblotting, Neutralization Studies
Ramos-DeSimone, N., et al. 1993. Hybridoma.12, 349.
Key Applications
Immunoblotting (Western Blotting)
Immunoprecipitation
Not Paraffin Sections
Neutralization Studies
Application Notes
Immunoblotting (2 µg/ml) Immunoprecipitation (see appplication references) Neutralization Studies (see comments and application references) Paraffin Sections (not recommended)
Application Comments
Inhibits MMP-9 enzymatic activity. For staining paraffin sections, use Anti-MMP-9 (626-644) (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37L). Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogen
MMP-9 from conditioned medium of PMA-stimulated HT-1080 human fibrosarcoma cells
Immunogen
Human
Clone
6-6B
Host
Mouse
Isotype
IgG₁
Species Reactivity
Human
Antibody Type
Monoclonal Antibody
Storage and Shipping Information
Ship Code
Ambient Temperature Only
Toxicity
Standard Handling
Storage
+2°C to +8°C
Do not freeze
Ok to freeze
Special Instructions
Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Resuspend the antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline, pH 7.4, to yield a final concentration of 100 µg/ml; product will be more stable if 0.1% sodium azide is included (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Freezing of aliquots is best for long-term storage of reconstituted product; repetitive freezing and thawing should be avoided.
Global Trade Item Number
카탈로그 번호
GTIN
IM09L-100UGCN
04055977228151
Documentation
Anti-MMP-9 (Ab-1) Mouse mAb (6-6B) Certificates of Analysis
Title
Lot Number
IM09L
References
참고문헌 보기
Cottam, D.W. and Rees, R.C. 1993. Intl. J. of Oncol.2, 861. Nakajima, M., et al. 1993. Cancer Res.53, 5802. Ramos-DeSimone, et al. 1993. Hybridoma. 12, 349. Stetler-Stevenson, W.G., et al. 1993. FASEB.7, 1434. Zucker, S., et al. 1993. Cancer Res.53, 140. Woessner, J.F. 1991. FASEB. 5, 2145. Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1; 99-106.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
27-August-2007 RFH
Synonyms
Anti-92 kDa Gelatinase, Anti-Matrix Metalloproteinase 9, Anti-Type IV Collagenase, Anti-Gelatinase B
Application
Immunoblotting (2 µg/ml) Immunoprecipitation (see appplication references) Neutralization Studies (see comments and application references) Paraffin Sections (not recommended)
Description
Purified mouse monoclonal antibody. Recognizes the ~92 kDa latent and the ~83 kDa active forms of human MMP-9 under non-reducing conditions, but only the latent form under reducing conditions.
Background
Matrix metalloproteinases (MMP's) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMP's share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis.
MMP-9 (Gelatinase B, 92 kDa gelatinase/type IV collagenase) is secreted as a 92 kDa zymogen which is proteolytically processed to the 83 kDa active form; a 68 kDa has also been detected. MMP-9, along with its most closely related member of the MMP family, MMP-2, show substrate specificity toward type IV and V collagens, gelatin and elastin. Numerous studies have shown a correlation between collagenase expression and metastatic potential. Elevated levels of MMP-9 in plasma suggest that it may be a useful marker for the diagnosis or prognosis of cancer in general.
Host
Mouse
Immunogen species
Human
Immunogen
MMP-9 from conditioned medium of PMA-stimulated HT-1080 human fibrosarcoma cells
Clone
6-6B
Isotype
IgG₁
Species
human
Positive control
MMP-9 protein (Cat. Nos. PF024 or PF038)
Form
Lyophilized
Formulation
Lyophilized from a volatile buffer, 100 µg BSA.
Preservative
None
Comments
Inhibits MMP-9 enzymatic activity. For staining paraffin sections, use Anti-MMP-9 (626-644) (Ab-3) Mouse mAb (56-2A4) (Cat. No. IM37L). Antibody should be titrated for optimal results in individual systems.
Storage
+2°C to +8°C
Do Not Freeze
Ok to freeze
Special Instructions
Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Resuspend the antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline, pH 7.4, to yield a final concentration of 100 µg/ml; product will be more stable if 0.1% sodium azide is included (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Freezing of aliquots is best for long-term storage of reconstituted product; repetitive freezing and thawing should be avoided.
Toxicity
Standard Handling
References
Cottam, D.W. and Rees, R.C. 1993. Intl. J. of Oncol.2, 861. Nakajima, M., et al. 1993. Cancer Res.53, 5802. Ramos-DeSimone, et al. 1993. Hybridoma. 12, 349. Stetler-Stevenson, W.G., et al. 1993. FASEB.7, 1434. Zucker, S., et al. 1993. Cancer Res.53, 140. Woessner, J.F. 1991. FASEB. 5, 2145. Liotta, L.A. and Stetler-Stevenson, W.G. 1990. in Seminars in Cancer Biology, ed. M.M. Gottesman. Vol. 1; 99-106.
Application references
Immunoprecipitation
Ramos-DeSimone, N. and French, D. L. 1994. Ann. NY Acad. Sci.732, 469.
Immunoblotting, Neutralization Studies
Ramos-DeSimone, N., et al. 1993. Hybridoma.12, 349.